In August 2009, the British Medical Journal published the first of multiple scientific articles that reported on an increased risk of blood clots from use of YAZ or YASMIN. At the time, these were the only 2 (two) trademarked DRSP (DROSPIRENONE) containing birth control pills. In the months leading up to that publication, the first of many lawsuits that have become known as YAZ CLAIMS, or a YAZ CLAIM, began to be filed in a number of venues.
In “Suits Claim Bayer’s YAZ Caused 50 Deaths; Novel Theory of Blood Clot Causation”, CBS NEWS’, Jim Edwards, explored reports from the National Law Journal and the onset of mass tort litigation over YAZ CLAIMS. At the time, it was reported that the theory of causation linking DRSP (DROSPIRENONE) to deaths and blood clots was novel or progressive. Since 2009 there have been multiple independent studies published, including an FDA funded study, that confirm an elevated risk of blood clots from use of a DRSP (DROSPIRENONE) containing birth control. Estimates of the risk vary as discussed elsewhere on this site. Regardless, the increased risk of blood clots has prompted the need for upgraded or updated warning labels. Most recently, in December 2011, a joint panel of FDA experts formed and Advisory Committee, to consider this issue and voted 21-5 that then current labeling did not properly or adequately reflect the increased risk. Additional FDA action on this vote is anticipated and arguably long overdue.
The term “YAZ CLAIM” is often used interchangeably with “YAZ CLAIMS” to describe a pending lawsuit or potential claim arising for personal injuries following use of a DRSP (DROSPIRENONE) containing birth control pill. What was thought to be a novel theory of causation, against a novel progestin, has now been backed by multiple studies confirming an elevated risk of blood clots. Additionally, the legal discovery process has revealed other information that supports related theories of liability, as well as the idea that the risks underlying pending YAZ CLAIMS were known to the manufacturer well before the pills were marketed.
FREE YAZ CLAIM EVALUATIONS are available through the sponsor of this site, Gabriel F. Zambrano, P.A.. Gabriel F. Zambrano, P.A., has been an early advocate of the increased risk of blood clots from DRSP (DROSPIRENONE) containing birth control pills and mass tort litigation in both the Federal Multi-District Litigation (MDL), as well as coordinated state court proceedings nationally.